Skip to main content

EQRx to Participate in the Jefferies 2022 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST.

A live and archived webcast of the fireside chat will be available by visiting the News & Events section of EQRx’s website, and selecting Events & Presentations, at investors.eqrx.com.

About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and health systems. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_US LinkedIn, Instagram: @eqrxinc.

EQRx™ and Remaking Medicine™ are trademarks of EQRx.

EQRx Contacts:

Media:
Dan Budwick
1AB
dan@1abmedia.com

Investors:
investors@eqrx.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  235.95
-7.01 (-2.89%)
AAPL  270.35
+0.34 (0.12%)
AMD  237.81
-8.46 (-3.43%)
BAC  53.88
-0.15 (-0.27%)
GOOG  339.00
-5.89 (-1.71%)
META  688.44
-17.97 (-2.54%)
MSFT  410.30
-13.07 (-3.09%)
NVDA  178.40
-7.21 (-3.88%)
ORCL  152.49
-7.57 (-4.73%)
TSLA  414.38
-7.43 (-1.76%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.